Evidence map›Paper›PMID 42640415›Full record

ArticleInternational urology and nephrology2026

LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study.

Michèle Alina Rytz, Saskia Hussung, Lorenz Frehner, Jörg Beyer, Laila Scheidewind, Beat Roth, Carmen Widmer, Aavash Baaral, Paola Francica, Mark A Rubin and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michèle Alina RytzDepartment of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland.
Saskia HussungDepartment of Medical Oncology and Hematology, University Hospital Zurich, University of Zurich, 8091, Zurich, Switzerland.
Lorenz FrehnerDepartment of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland.
Jörg BeyerDepartment of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland.
Laila ScheidewindDepartment of Urology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland.
Beat RothDepartment of Urology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland.
Carmen WidmerDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Aavash BaaralDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Paola FrancicaDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Mark A RubinDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Sven RottenbergDepartment for BioMedical Research, University of Bern, 3008, Bern, Switzerland.
Antonio Rodriguez-Calero *Institute of Tissue Medicine and Pathology, University of Bern, 3008, Bern, Switzerland.
Dilara Akhoundova *Department of Medical Oncology, University Hospital of Bern, Inselspital, University of Bern, 3010, Bern, Switzerland. dilara.akhoundovasanoyan@insel.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite recent therapeutic advances, platinum-based chemotherapy still remains a cornerstone in the treatment of muscle invasive bladder cancer (MIBC). We investigated the association between leucine-rich-repeat-containing 8A (LRRC8A) expression, a protein with a potential mechanistic role in platinum-sensitivity, and clinical outcomes following neoadjuvant chemotherapy in MIBC.

methodsWe histologically characterized transurethral resection of bladder tumor (TUR-B) and cystectomy MIBC samples. We analyzed membranous and cytoplasmic tumor expression levels of LRRC8A, correlating results with clinical outcomes.

resultsWe analyzed clinical data from 35 MIBC patients treated at the University Hospital of Bern between September 2017 and March 2023. Immunohistochemistry (IHC) expression was assessed for 17 patients with paired TUR-B and cystectomy samples. High membranous LRRC8A expression was observed more frequently in patients achieving a complete pathologic response (tumor regression grade [TRG] 1) than in those with TRG2 or TRG3 (3/5 [60%] vs. 2/12 [16.7%]); however, this difference did not reach statistical significance. Kaplan-Meier survival analysis showed no statistically significant difference in overall survival (OS) between patients with negative/low versus high membranous LRRC8A.

conclusionsOur data suggest a potential association of LRRC8A expression levels with cisplatin sensitivity in MIBC. Given the limited sample size and retrospective nature of the study, these findings should be considered preliminary, exploratory and hypothesis-generating. Further validation in larger, independent cohorts, as well as functional studies, will be needed.

Indexed as

CisplatinLRRC8AMuscle-invasive bladder cancer (MIBC)Neoadjuvant chemotherapy (NAC)Tumor regression grade (TRG)

Identifiers

PMID42640415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.